Allogeneic human neural stem cells for improved therapeutic delivery to peritoneal ovarian cancer.
Stem Cell Res Ther
; 12(1): 205, 2021 03 24.
Article
in En
| MEDLINE
| ID: mdl-33761999
ABSTRACT
BACKGROUND:
Immortalized, clonal HB1.F3.CD 21 human neural stem/progenitor cells (NSCs), loaded with therapeutic cargo prior to intraperitoneal (IP) injection, have been shown to improve the delivery and efficacy of therapeutic agents in pre-clinical models of stage III ovarian cancer. In previous studies, the distribution and efficacy of the NSC-delivered cargo has been examined; however, the fate of the NSCs has not yet been explored.METHODS:
To monitor NSC tropism, we used an unconventional method of quantifying endocytosed gold nanorods to overcome the weaknesses of existing cell-tracking technologies.RESULTS:
Here, we report efficient tumor tropism of HB1.F3.CD 21 NSCs, showing that they primarily distribute to the tumor stroma surrounding individual tumor foci within 3 h after injection, reaching up to 95% of IP metastases without localizing to healthy tissue. Furthermore, we demonstrate that these NSCs are non-tumorigenic and non-immunogenic within the peritoneal setting.CONCLUSIONS:
Their efficient tropism, combined with their promising clinical safety features and potential for cost-effective scale-up, positions this NSC line as a practical, off-the-shelf platform to improve the delivery of a myriad of peritoneal cancer therapeutics.Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Ovarian Neoplasms
/
Hematopoietic Stem Cell Transplantation
/
Neural Stem Cells
Limits:
Female
/
Humans
Language:
En
Journal:
Stem Cell Res Ther
Year:
2021
Document type:
Article
Affiliation country:
Estados Unidos